Adaptimmune Therapeutics PLC — Director's Dealing 2021

Jan 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2021-01-11

Reporting Person: Norry Elliot (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-11	Option to purchase Ordinary Shares	$1.03	A	1086816	Acquired	2031-01-11	Ordinary Shares (1086816)	Direct
2021-01-11	Option to purchase Ordinary Shares	$0.0014	A	242712	Acquired		Ordinary Shares (242712)	Direct

Footnotes

F1: The exercise price was converted from GBP0.76 based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 271,704 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in monthly installments of 22,638 Ordinary Shares on the eleventh of each month from February 11, 2022 through December 11, 2024 and 22,782 Ordinary Shares on January 11, 2025.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.358422 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 60,678 Ordinary Shares on January 11, 2022 and will be exercisable as to the remainder in annual installments of 60,678 Ordinary Shares on the eleventh of each January from January 11, 2023 through January 11, 2025.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.